Navigation Links
Experimental Drug May Prevent Plaque Buildup
Date:2/20/2009

Further study, though, could reveal pitfalls, expert warns

FRIDAY, Feb. 20 (HealthDay News) -- An experimental drug called A-002 appears effective in preventing atherosclerosis, according to a phase II study that included American and Ukrainian participants.

In atherosclerosis, arteries become blocked and inflamed by a buildup of white blood cells and fatty material, or lipids. Two potentially bioactive fats that can be involved in atherosclerosis are produced when enzymes known as sPLA2 break down particular molecules in the blood and artery walls. The drug A-002 targets three groups of these enzymes that are present in high levels in atherosclerotic lesions.

The 393 people in the study were randomly selected to receive one of four doses of the drug (50, 100, 250 or 500 milligrams) or a placebo twice a day for eight weeks.

Among people taking any dose of A-002, average enzyme levels decreased by 87 percent, compared with a 5 percent drop in the placebo group. The reduction varied by dosage, ranging from an average of 69 percent for those taking 50 mg to 96 percent for people taking 500 mg.

Average levels of low-density lipoprotein cholesterol (the bad type) decreased by 8 percent among people given A-002, compared with a 1.7 percent decline in the placebo group. Concentrations of the inflammatory marker C-reactive protein fell by 56 percent among people taking the drug and 25 percent among those given the placebo.

The findings appear in this week's issue of The Lancet.

"Our study demonstrates that sPLA2 inhibition produces favorable changes in plasma lipids, oxidized LDL and inflammatory markers, and the magnitude of these changes was larger in statin-treated patients," Dr. Robert S. Rosenson, a specialist in cardiovascular medicine at the University of Michigan Medical School, and colleagues wrote.

Though Rosenson said that further study is needed to determine "the effects of sPLA2 inhibition on reducing atherosclerosis progression and cardiovascular events," the study's conclusion suggested that "the reductions in sPLA2 concentration suggest that A-002 might be an effective anti-atherosclerotic agent."

In an accompanying editorial in The Lancet, Dr. Marshall A. Corson, of the University of Washington/Harborview Medical Center in Seattle, noted that a number of other seemingly promising anti-inflammatory or antioxidant therapies eventually proved ineffective or harmful.

This "suggests that challenges might lie ahead for sPLA2 inhibitors," Corson wrote. "These difficulties could increase the regulatory hurdles that need to be cleared for these, or other, novel anti-atherosclerotic therapies."

More information

The U.S. National Heart, Lung, and Blood Institute has more about atherosclerosis.



-- Robert Preidt



The Lancet, news release, Feb. 19, 2009


'/>"/>
Copyright©2009 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Experimental anti-cancer drug made from corn lillies kills brain tumor stem cells
2. Experimental Antidepressants Offer Faster Relief
3. Experimental drug shows promise in advanced kidney cancer
4. Experimental drug boosts survival in recurrent ovarian cancer
5. Experimental cancer pharmaceuticals under trial
6. Experimental Drug Fails Against Heart Failure
7. Experimental Drug Fights Prostate Cancer
8. Experimental technique at GUMC offers real-time analysis of breast cancer biopsies
9. Experimental Vaccine Halts Prostate Cancer in Mice
10. Experimental Biology 2008 Todays Research: Tomorrows Health, April 5-9
11. 52 minority scientists receive travel fellowships to Experimental Biology 2008
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Experimental Drug May Prevent Plaque Buildup
(Date:6/25/2016)... ... June 25, 2016 , ... ... issues and applications at AcademyHealth’s Annual Research Meeting June 26-28, 2016, at the ... several important health care topics including advance care planning, healthcare costs and patient ...
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, Dr. Omkar Marathe ... from the David Geffen School of Medicine at UCLA. He trained in Internal Medicine ... his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had the ...
(Date:6/24/2016)... ... ... Those who have experienced traumatic events may suffer from a complex set of ... or alcohol abuse, as a coping mechanism. To avoid this pain and suffering, Serenity ... event. , Trauma sufferers tend to feel a range of emotions, from depression, guilt, ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... now offering micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has extensive experience with ... Damon brackets , AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation is a ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Haute Beauty Network, ... M. Weintraub as a prominent plastic surgeon and the network’s newest partner. ... the most handsome men, look naturally attractive. Plastic surgery should be invisible.” He ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)...   Pulmatrix, Inc ., (NASDAQ: PULM ... announced today that it was added to the Russell ... comprehensive set of U.S. and global equity indexes on ... milestone for Pulmatrix," said Chief Executive Officer Robert ... progress in developing drugs for crucial unmet medical needs, ...
(Date:6/23/2016)... Any dentist who has made an implant supported ... Many of them do not even offer this as a ... laboratory costs involved. And those who ARE able to offer ... high cost that the majority of today,s patients would not ... Zadeh , founder of Dental Evolutions Inc. and inventor of ...
(Date:6/23/2016)... 23, 2016 Capricor Therapeutics, ... a biotechnology company focused on the discovery, development ... patient enrollment in its ongoing randomized HOPE-Duchenne clinical ... 50% of its 24-patient target. Capricor expects the ... quarter of 2016, and to report top line ...
Breaking Medicine Technology: